Lantheus Medical Imaging Inc. sealed a new purchasing deal with Ottawa-based MDS Nordion for a rare imaging isotope, molybdenum-99.
The Billerica, Mass.-based medical imaging company will begin receiving a weekly supply of Mo-99 when the National Research Universal reactor in Chalk River, Ontario, goes back online, expected the end of July. The contract is good through July 2011.
Mo-99 is the parent isotope of the technetium-99m isotope commonly used in medical imaging. Lantheus needs Mo-99 to fuel its TechneLite generators to make Te-99m. Lantheus vice president of manufacturing and supply chain Bill Dawes said in prepared remarks that the company is committed to helping "stabilize the worldwide Mo-99 shortage." Molybdenum-99 has a half-life of just 2.74 days and is very rare.
Lantheus is in the process of increasing its suppliers for the isotope. In May, the company gained increased access to Mo-99 from the Nuclear Reactor Institute, resulting from a partnership between the Institute for Radioelements in Fleurus, Belgium, and the Rez, Czech Republic-based Nuclear Research Institute.
Last summer Lantheus inked a deal with the Australian Nuclear Science and Technology Organization to receive Mo-99. In March, Mansfield, Mass.-based Covidien plc (NYSE:COV) inked a similar deal with the Polish Institute of Atomic Energy’s Maria reactor.
On December 11-12,DeviceTalks West is taking over Orange County's medtech industry with one of the most anticipated conferences of the winter, bringing you the best and brightest minds in the industry.
Dr. Robert Greenberg, Executive Chairman, Alfred E. Mann Foundation
Gary Guthart, President and Chief Executive Officer, Intuitive Surgical
Reggie Groves, CEO, REVA Medical
Use code KEYNOTE to save an additional 10%.